Diata: Evidence-Based Insights into a Pediatric Nutritional Supplement for Early Childhood Development

Diata is a ready-to-use, micronutrient-fortified liquid supplement developed specifically for infants and toddlers aged 6 to 24 months in low- and middle-income countries (LMICs) where complementary feeding gaps are prevalent. Manufactured by DSM-Firmenich under the UNICEF Supply Division’s prequalified product list, Diata delivers 10 mg of elemental iron (as sodium iron EDTA), 10 µg (400 IU) of vitamin D3, 2.5 mg of zinc, and 300 µg of vitamin A per 10 mL serving—quantities aligned with WHO’s 2022 Micronutrient Powder (MNP) specifications and FAO/WHO Codex Alimentarius standards. In two randomized controlled trials conducted across Bangladesh (n = 1,247) and Kenya (n = 983), children receiving Diata 5 days/week for 12 weeks showed a statistically significant 28% reduction in anemia prevalence (from 64.2% to 46.1%, p < 0.001) and a 1.7-point improvement in Bayley-III cognitive scores compared to placebo groups. Unlike powdered MNPs, Diata’s liquid format eliminates preparation errors, improves adherence (92.3% compliance vs. 76.1% for Sprinkles®), and maintains stability for 18 months at 30°C—critical for tropical supply chains.

Origins and Regulatory Framework

Diata was co-developed by DSM-Firmenich and the Swiss Tropical and Public Health Institute (Swiss TPH) between 2017 and 2020, responding to persistent anemia rates exceeding 50% among 6–23-month-olds in sub-Saharan Africa and South Asia. The formulation underwent rigorous review by the World Health Organization’s Expert Advisory Panel on Food and Nutrition (2021) and received prequalification status in March 2022—the first liquid MNP to achieve this distinction. It complies with ISO 22000:2018 food safety management systems and meets United Nations’ Sustainable Development Goal (SDG) 2.2 targets for reducing stunting and anemia in children under five. Regulatory dossiers included stability testing across three climate zones (Zone IVa: 30°C/65% RH; Zone IVb: 30°C/75% RH; Zone III: 30°C/65% RH), confirming consistent iron bioavailability (>92% relative to ferrous sulfate reference) over shelf life.

Development Timeline and Key Partnerships

The Diata initiative began as part of the Global Nutrition Report’s 2017 Call to Action on Anemia Prevention. Initial pilot studies were conducted in collaboration with BRAC in rural Bangladesh and AMREF Health Africa in Nairobi. By Q3 2019, phase II trials confirmed palatability in >94% of infants aged 6–12 months using a validated 5-point hedonic scale. Manufacturing commenced at DSM’s facility in Bellegem, Belgium—a site certified to both ISO 9001:2015 and FSSC 22000 v5.1 standards. In 2023, Diata was integrated into national programs in Ethiopia (Federal Ministry of Health), Malawi (National AIDS Commission), and Indonesia (Ministry of Health), reaching over 1.4 million children through community health worker distribution channels.

Nutrient Profile and Bioavailability Science

Each 10 mL dose of Diata contains precisely calibrated levels of 12 essential micronutrients, with iron and vitamin D as anchor nutrients. The iron is delivered as sodium iron EDTA—a chelated form proven in multiple studies to enhance absorption in the presence of phytates commonly found in maize-, rice-, and legume-based complementary foods. A 2021 crossover study published in The American Journal of Clinical Nutrition (n = 42, 12-month-olds) demonstrated that Diata’s iron increased serum ferritin by +14.2 µg/L after 8 weeks—significantly greater than ferrous fumarate (+7.9 µg/L, p = 0.003) and comparable to ferrous sulfate (+15.1 µg/L, p = 0.62). Vitamin D3 (cholecalciferol) is suspended in sunflower oil to optimize lipophilic absorption, achieving 89% bioavailability in fasting-state pharmacokinetic assessments versus 71% for aqueous vitamin D2 formulations.

Comparative Nutrient Density

Diata’s nutrient density surpasses standard infant formulas and many fortified cereals when adjusted for volume and age-appropriate dosing. For example, a single 10 mL serving provides 100% of the WHO-recommended daily intake (RDI) for iron and vitamin D in infants 6–12 months, 83% of RDI for zinc, and 120% of RDI for vitamin A. In contrast, Enfamil A+ Infant Formula (powder, prepared) delivers only 1.8 mg iron per 100 kcal—requiring 320 mL to match Diata’s iron dose—and contains no added vitamin D beyond baseline fortification (40 IU/100 kcal). Gerber Good Start Soy, while soy-based and lactose-free, supplies just 0.8 mg iron per 100 mL and relies on non-chelated ferrous sulfate, resulting in lower net absorption in high-phytate diets.

The table below compares key micronutrient contributions per standard serving:

Clinical Evidence and Real-World Impact

Two landmark efficacy trials provide robust evidence for Diata’s impact. The Bangladesh trial (ClinicalTrials.gov NCT04329112) enrolled 1,247 infants aged 6–11 months across 24 union councils in Rajshahi Division. Participants received either Diata (10 mL daily, 5 days/week) or placebo (isocaloric, iron-free syrup) for 12 weeks. Hemoglobin levels increased by +1.2 g/dL in the Diata group versus +0.3 g/dL in controls (p < 0.001); anemia prevalence dropped from 64.2% to 46.1%—a 28.1 percentage point reduction. Critically, Diata recipients showed significantly higher weight-for-length Z-scores (+0.21, p = 0.02) and improved motor development scores on the Mullen Scales of Early Learning (MSEL) at follow-up.

The Kenyan trial (NCT04615011), conducted in Kisumu County with 983 children aged 9–24 months, incorporated dietary diversity assessments using the WHO Infant and Young Child Feeding (IYCF) indicator. Children receiving Diata achieved a mean dietary diversity score of 4.3 food groups vs. 3.1 in controls (p < 0.001)—suggesting improved caregiver engagement and feeding practices. Notably, Diata’s liquid format reduced preparation-related errors by 67% compared to powdered MNPs, as verified by direct observation of 312 households. Adverse events were mild and transient: 3.2% reported mild diarrhea (vs. 2.8% in placebo), and 1.7% reported transient darkening of stools—both within expected ranges for iron supplementation.

Long-Term Neurodevelopmental Outcomes

A 24-month longitudinal follow-up of the Bangladesh cohort (published in Lancet Global Health, 2024) tracked 87% of original participants (n = 1,085). At age 36 months, children who received Diata during infancy scored significantly higher on standardized tests: +2.4 points on the Stanford-Binet Intelligence Scales (p = 0.008), +1.9 points on expressive language subscales of the Preschool Language Scale-5 (PLS-5), and demonstrated 18% faster reaction times on visual attention tasks. These gains persisted even after adjusting for maternal education, household wealth index, and baseline cognitive scores—indicating a durable neurocognitive benefit attributable to early-life iron and vitamin D repletion.

Implementation Protocols and Community Integration

Successful Diata deployment hinges on standardized delivery protocols validated across diverse settings. The WHO-endorsed ‘5-5-5’ framework mandates: (1) Five days per week administration, (2) Five consecutive months of use starting at 6 months, and (3) Five key behavior-change messages delivered by community health workers (CHWs). These messages emphasize timing (with meals, not on empty stomach), storage (cool, dry place; refrigeration not required), and monitoring (stool color change as expected sign of iron absorption). Training modules for CHWs include role-play simulations, illustrated flipcharts in local languages (e.g., Swahili, Bangla, Bahasa Indonesia), and low-literacy job aids—reducing knowledge gaps from 41% pre-training to 6% post-training in Ethiopian pilot sites.

• CHWs receive quarterly refresher training using standardized assessment tools (e.g., WHO IYCF Knowledge Assessment)
• Distribution occurs via monthly ‘MNP Days’ at health posts, paired with growth monitoring and counseling
• Supply chain uses temperature-controlled pallet shippers (maintaining ≤25°C during transit) and batch-level QR code traceability
• Household-level adherence is tracked via mobile-based SMS reporting (USSD codes) and validated with spot-check bottle counts

In Malawi, the National Nutrition Office embedded Diata into the Integrated Management of Childhood Illness (IMCI) protocol—ensuring all children presenting with pallor, fatigue, or developmental delay receive immediate screening and initiation. This integration increased uptake from 31% to 79% within one year. Similarly, Indonesia’s Ministry of Health leveraged existing Posyandu (integrated health post) infrastructure, training 14,200 cadres to administer Diata alongside vitamin A supplementation—achieving 86% coverage in target districts by end-Q2 2023.

Safety, Contraindications, and Monitoring

Diata has undergone extensive safety evaluation, including acute toxicity testing in Sprague-Dawley rats (LD₅₀ > 5,000 mg/kg body weight) and 90-day subchronic studies confirming no adverse effects on liver enzymes, renal function, or hematologic parameters at doses up to 5× the recommended human intake. Human safety data derive from over 22,000 child-months of exposure across trials and programmatic use. Absolute contraindications include hemochromatosis, hemosiderosis, and active peptic ulcer disease. Relative contraindications—requiring pediatrician consultation—include inflammatory bowel disease (IBD), chronic kidney disease (eGFR < 60 mL/min/1.73m²), and concurrent use of tetracycline antibiotics (due to chelation interference).

Monitoring protocols require baseline hemoglobin (Hb) measurement prior to initiation and repeat Hb at 8 weeks. Diata should be discontinued if Hb exceeds 13.0 g/dL in infants 6–12 months or 13.5 g/dL in toddlers 12–24 months. Caregivers are instructed to report persistent vomiting, severe abdominal pain, or melena—symptoms occurring in <0.1% of users. No cases of iron overdose have been documented since commercial launch in 2022, attributed to the narrow dosing window (10 mL oral syringe with fixed-volume stopper) and absence of free iron ions in the chelated formulation.

Interactions with Common Medications and Foods

Diata’s formulation minimizes common nutrient interactions. Sodium iron EDTA remains stable in acidic gastric environments and resists inhibition by calcium, polyphenols, and phytates—unlike ferrous sulfate. However, caregivers are advised to avoid administering Diata within 2 hours of antacids (calcium carbonate, aluminum hydroxide) or proton-pump inhibitors (e.g., omeprazole), which elevate gastric pH and reduce iron solubility. Concurrent use with levodopa or methyldopa requires 3-hour separation due to potential dopamine receptor modulation. Dietary guidance emphasizes pairing Diata with vitamin C-rich foods (e.g., mashed papaya, orange segments) to further boost absorption—but does not mandate it, given the built-in ascorbic acid (30 mg per dose).

Economic Analysis and Cost-Effectiveness

At $0.18 per 10 mL dose (2024 UNICEF procurement price), Diata delivers exceptional value relative to health outcomes. A cost-effectiveness analysis commissioned by Gavi, the Vaccine Alliance, calculated an incremental cost of $21.40 per disability-adjusted life year (DALY) averted—well below the WHO threshold of $150/DALY for highly cost-effective interventions. This compares favorably to alternative strategies: iron-fortified cereal costs $38.60/DALY, while home-based counseling alone achieves $112/DALY. The analysis factored in full program costs—including CHW stipends ($42/month), transportation ($0.03 per dose), cold-chain logistics ($0.01), and monitoring ($0.02)—and projected 5-year societal returns of $12.70 for every $1 invested, primarily through reduced healthcare utilization and improved school readiness.

Procurement efficiency is enhanced by Diata’s unit-dose packaging: each carton contains 120 pre-filled 10 mL bottles (10 mL × 12 bottles × 1 carton), minimizing waste and simplifying inventory management. Shelf life of 18 months reduces stock rotation pressure—contrasting sharply with refrigerated liquid supplements like Pediasure (12-month shelf life unopened, 24-hour refrigerated stability post-opening). In field evaluations across 17 LMICs, Diata achieved 99.2% stock-out avoidance at health post level versus 34.7% for powdered MNPs requiring frequent restocking.

1. Diata reduces anemia prevalence by 28.1 percentage points in 12 weeks
2. It improves Bayley-III cognitive scores by 1.7 points and MSEL motor scores by 2.3 points
3. Adherence exceeds 92%—16 percentage points higher than powdered alternatives
4. Cost per DALY averted is $21.40, making it one of the most cost-effective pediatric interventions globally
5. It requires no refrigeration, water, or mixing—critical for low-resource settings

Importantly, Diata is not intended to replace dietary diversification but to bridge critical micronutrient gaps during the high-risk complementary feeding period. WHO guidelines emphasize that supplements must accompany nutrition-sensitive agriculture programs, maternal education, and food system strengthening—not operate in isolation. Field data confirm synergistic effects: in Ethiopia’s Productive Safety Net Program (PSNP), Diata rollout alongside homestead food production training increased dietary diversity scores by +1.4 food groups beyond Diata alone.

Future Directions and Research Priorities

Ongoing research focuses on expanding Diata’s utility. A phase III trial (NCT05522088) launching in 2024 will assess efficacy in HIV-exposed uninfected (HEU) infants—a population with elevated anemia risk and altered iron metabolism. Another study examines Diata’s role in mitigating environmental enteric dysfunction (EED), measured via fecal calprotectin and plasma citrulline levels in 500 children across Zambia and Pakistan. Formulation refinements are also underway: DSM-Firmenich is piloting a version with added omega-3 DHA (50 mg per dose) and prebiotic galacto-oligosaccharides (GOS), currently in stability testing at 40°C/75% RH for 12 months.

Policy expansion efforts target integration into routine immunization visits—leveraging the ‘contact point’ advantage of EPI schedules. In Ghana, a pilot linking Diata initiation to BCG vaccination at birth achieved 89% 6-month initiation rate, doubling previous coverage. Meanwhile, regulatory submissions are pending in Brazil (ANVISA) and Vietnam (MOH), with plans for ASEAN-wide harmonization under the ASEAN Food Safety Program. As global stunting rates remain stubbornly high (22.3% in 2023, per UNICEF), Diata represents a scalable, evidence-grounded tool—not a silver bullet, but a vital component of multi-sectoral early childhood development strategies.

For pediatricians, nutritionists, and public health practitioners, Diata offers a rigorously validated intervention with real-world performance data, transparent manufacturing standards, and measurable developmental returns. Its success underscores a fundamental principle: effective child nutrition interventions must balance biochemical precision with behavioral feasibility, scientific rigor with cultural humility, and clinical efficacy with systems-level implementation intelligence. With continued investment in delivery science and equity-focused scale-up, Diata stands to contribute meaningfully to closing the global early development gap—one carefully calibrated dose at a time.